The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 2.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (4 analysts) rates it none, with a mean price target of $6.
Cytek BioSciences Inc
CTKB · NASDAQ · USD · Market cap $597M · 678 employees
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications.
FAIL · Does not pass the screenPrice as of 13 Nov 2026Daily close, not a live quoteLast reviewed 4 days ago
Screened 2026-11-13 · the tape above runs as of 04:19 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price5.84 USD at the 13 Nov 2026 close
- Our value readOvervalued vs our fair value, as of 13 Nov 2026
- Our regime readMarkup, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans to puts (put/call 1.20)
- Last reviewed13 Nov 2026 (4 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $3.88 to $4.46, base estimate $3.88 (screen dated 2026-11-13).
- Trend Markup
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 1.20, read 2026-11-14
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markup label.
Cytek BioSciences Inc holds its Markup at $5.84. Consolidating, no directional conviction, held for 83 days.
| Phase | Markup |
| Quantitative state | Consolidating, no directional conviction, held for 83 days |
| Price at the screen | $5.84 |
| Valuation | N/A trailing · 26.40 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 1.17 |
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 5.14% | Below 33% | Interest-bearing debt is just 5.1% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 36.98% | Below 33% | Interest-bearing cash and securities are 37.0% of assets, above the one-third limit. | Fail |
| Receivables | 33.23% | Below 49% | Money owed to the company is 33.2% of assets, under the 49% limit. | Pass |
| Revenue purity | 1.10% | Below 5% | Only 1.1% of revenue comes from non-compliant sources, under the 5% line. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
Cytek BioSciences's business is fine, but its cash and interest-bearing securities are about 37% of its assets, just over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-15. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when CTKB's ethical verdict changes
Today CTKB does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Overvalued vs our fair value, as of 13 Nov 2026: it trades above our $3.88 fair value estimate, none competitive moat, 6.50% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-13 screen. The gold marker is the market price at the same screen. The price runs 50.5% above the base estimate.
Third-party analyst targets: 4 covering, consensus Buy. The average target sits −10% from the screen price.
Reading the gap · Both our model and the Street see limited upside at this price.
Price History & ProjectionsWhere our models see it going: fair-value estimate $3.88, with a range of $3.88 to $4.46, dated to the 2026-11-13 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsWhy it gives us pause
At 26.4x forward earnings, the price already runs ahead of the business. It trades 51% above our $3.88 fair value, so you would be buying at a premium, not a discount. The none moat is real, but quality alone does not make an expensive price cheap.
| Forward P/E | 26.4xexpensive even after accounting for its growth |
| EPS, trailing | -0.58 |
| EPS, forward | 0.20 |
| Revenue growth | +6.5%slow but positive growth |
| Profit margin | -36.2%currently unprofitable |
| Return on equity | -20.9%not currently earning a positive return on equity |
| FCF yield | 1.07% |
| Debt to equity | 0.08minimal debt: a conservative balance sheet |
| Current ratio | 4.69comfortably covers its short-term bills |
| Beta | 1.17moves a little more than the market |
| Short interest, float | 0.03% |
| 52-week range | 3.09 - 6.18 |
| Moat | NONE |
| Market cap | $597M |
| Employees | 678 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeCTKB trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 2.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bearish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (4 analysts) rates it none, with a mean price target of $6. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bearish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (4 analysts) rates it none, with a mean price target of $6. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bearish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (4 analysts) rates it none, with a mean price target of $6. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 2.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bearish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (4 analysts) rates it none, with a mean price target of $6. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bearish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (4 analysts) rates it none, with a mean price target of $6. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 12.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bearish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (4 analysts) rates it none, with a mean price target of $6. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 3.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bearish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (4 analysts) rates it none, with a mean price target of $6. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bearish. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (4 analysts) rates it none, with a mean price target of $6. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (4 analysts) rates it none, with a mean price target of $6.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $4.12 | -1.3% | · | $987 | -1.3% |
| 2 months | $4.53 | -10.3% | · | $897 | -10.3% |
| 3 months | $4.00 | +1.6% | · | $1,016 | +1.6% |
| 6 months | $4.97 | -18.2% | · | $818 | -18.2% |
| 1 year | $3.47 | +17.2% | · | $1,172 | +17.2% |
| 2 years | $6.01 | -32.4% | · | $676 | -32.4% |
| 3 years | $8.10 | -49.8% | · | $502 | -49.8% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever CTKB does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.